Covid-19 Breakthrough Infections in Vaccinated Health Care Workers

Moriah Bergwerk, Tal Gonen, Yaniv Lustig, +13

New England Journal of Medicine

BNT162b2 COVID-19 vaccine and correlates of humoral immune responses and dynamics: a prospective, single-centre, longitudinal cohort study in health-care workers

Yaniv Lustig, Einav Sapir, Gili Regev‐Yochay, +13

The Lancet Respiratory Medicine

VaccinationVaccinologyLongitudinal Cohort StudyBnt162b2 Covid-19 VaccineHumoral Response +7

Systemic and mucosal IgA responses are variably induced in response to SARS-CoV-2 mRNA vaccination and are associated with protection against subsequent infection

Salma Sheikh‐Mohamed, Baweleta Isho, Gary Chao, +37

Mucosal Immunology

VaccinationSaliva Iga ResponseMucosal VaccinationVaccine DevelopmentSars-cov-2 Mrna Vaccination +11

Immunogenicity and safety of the BNT162b2 mRNA COVID-19 vaccine in people living with HIV-1

Itzchak Levy, Anat Wieder-Finesod, Vladyslav Litchevsky, +11

Clinical Microbiology and Infection

Maternal-neonatal transfer of SARS-CoV-2 immunoglobulin G antibodies among parturient women treated with BNT162b2 messenger RNA vaccine during pregnancy

Omer Nir, A. Schwartz, Shlomi Toussia‐Cohen, +8

American Journal of Obstetrics & Gynecology MFM

Decreased infectivity following BNT162b2 vaccination: A prospective cohort study in Israel

Gili Regev‐Yochay, Sharon Amit, Moriah Bergwerk, +14

The Lancet Regional Health - Europe

Superior immunogenicity and effectiveness of the third compared to the second BNT162b2 vaccine dose

Yaniv Lustig, Tal Gonen, Lilac Meltzer, +13

Nature Immunology

VaccinationVaccine SafetyVaccinologyVaccine DevelopmentImmunology +5

BNT162b2 mRNA COVID-19 vaccination in immunocompromised patients: A prospective cohort study

Galia Rahav, Yaniv Lustig, Jacob Lavee, +16

EClinicalMedicine

Testing IgG antibodies against the RBD of SARS-CoV-2 is sufficient and necessary for COVID-19 diagnosis

Victoria Indenbaum, Ravit Koren, Shiri Katz-Likvornik, +16

PLoS ONE

VaccinationDiagnostic VirologyIgg Antibody LevelsViral DiagnosticsMedicine +11

Early Immunogenicity and Safety of the Third Dose of BNT162b2 Messenger RNA Coronavirus Disease 2019 Vaccine Among Adults Older Than 60 Years: Real-World Experience

Mayan Gilboa, Michal Mandelboim, Victoria Indenbaum, +14

The Journal of Infectious Diseases